Gilead Sciences将2026财年调整后的每股收益指导从8.45美元-8.85美元下调至（1.05）美元-（0.65）美元，而Est为8.66美元

2026-05-08 04:04

GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE(1)
(unaudited)

(in millions, except percentages and per share amounts)	Provided February 10, 2026	Updated May 7, 2026
Projected product gross margin GAAP to non-GAAP reconciliation:
GAAP projected product gross margin	~ 79.0%	~ 79.0%
Acquisition-related expenses	~ 8.0%	~ 8.0%
Non-GAAP projected product gross margin	~ 87.0%	~ 87.0%

Projected operating income (loss) GAAP to non-GAAP reconciliation:
GAAP projected operating income (loss)	$11,400 - $11,900	$(1,000) - $(500)
Acquisition-related, restructuring and other expenses	~ 2,400	~ 3,400
Non-GAAP projected operating income	$13,800 - $14,300	$2,400 - $2,900

Projected effective tax rate GAAP to non-GAAP reconciliation:(2)
GAAP projected effective tax rate	~ 21%	~ (150%) - (220%)
Income tax effect of above non-GAAP adjustments and fair value adjustments of equity securities, and discrete and related tax adjustments	(~ 1%)	NM
Non-GAAP projected effective tax rate	~ 20%	~ 190% - 140%

Projected diluted earnings (loss) per share GAAP to non-GAAP reconciliation:
GAAP projected diluted earnings (loss) per share	$6.75 - $7.15	$(3.25) - $(2.85)
Acquisition-related, restructuring and other expenses, fair value adjustments of equity securities and discrete and related tax adjustments	~ 1.70	~ $2.20
Non-GAAP projected diluted earnings (loss) per share	$8.45 - $8.85	$(1.05) - $(0.65)